For those who want to look at the pretty pictures, the paper is open access (which costs money- in this case money well spent):
Lancet Oncology has an impact factor of 41, which (after a quick google) makes it the 33rd highest impact factor journal.
This is skewed by the fact that most of the top impact journals are medical and in particular cancer related, but still, it's significant to note that the paper is published in a general oncology journal, not a radiopharm journal; those seem to be fairly niche with impact factors <10.
In other words, this is a high level journal publication.
(I presume The Lancet is a bit like Nature- once there was only the main journal, now there are also a bunch of "baby journals" in various medical subfields)
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00402-9/fulltext
For those who want to look at the pretty pictures, the paper is...
-
- There are more pages in this discussion • 126 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.22 |
Change
0.060(0.28%) |
Mkt cap ! $7.101B | |||
| Open | High | Low | Value | Volume |
| $21.14 | $21.40 | $20.75 | $16.20M | 767.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 120 | $21.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.25 | 457 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| TLX (ASX) Chart |